Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma
[Image: see text] Non-small cell lung carcinoma (NSCLC) is the most common cancer globally. Phytochemicals and small molecule inhibitors significantly prevent varying types of cancers, including NSCLC. These therapeutic molecules serve as important sources for new drugs that interfere with cellular...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398694/ https://www.ncbi.nlm.nih.gov/pubmed/37546685 http://dx.doi.org/10.1021/acsomega.3c02424 |
_version_ | 1785084105924280320 |
---|---|
author | Hasan, Gulam Mustafa Hassan, Md. Imtaiyaz Sohal, Sukhwinder Singh Shamsi, Anas Alam, Manzar |
author_facet | Hasan, Gulam Mustafa Hassan, Md. Imtaiyaz Sohal, Sukhwinder Singh Shamsi, Anas Alam, Manzar |
author_sort | Hasan, Gulam Mustafa |
collection | PubMed |
description | [Image: see text] Non-small cell lung carcinoma (NSCLC) is the most common cancer globally. Phytochemicals and small molecule inhibitors significantly prevent varying types of cancers, including NSCLC. These therapeutic molecules serve as important sources for new drugs that interfere with cellular proliferation, apoptosis, metastasis, and angiogenesis by regulating signaling pathways. These molecules affect several cellular signaling cascades, including p53, NF-κB, STAT3, RAS, MAPK/ERK, Wnt, and AKT/PI3K, and are thus implicated in the therapeutic management of cancers. This review aims to describe the bioactive compounds and small-molecule inhibitors, their anticancer action, and targeting cellular signaling cascades in NSCLC. We highlighted the therapeutic potential of Epigallocatechin gallate (EGCG), Perifosine, ABT-737, Thymoquinine, Quercetin, Venetoclax, Gefitinib, and Genistein. These compounds are implicated in the therapeutic management of NSCLC. This review further offers deeper mechanistic insights into different signaling pathways that could be targeted for NSCLC therapy by phytochemicals and small-molecule inhibitors. |
format | Online Article Text |
id | pubmed-10398694 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-103986942023-08-04 Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma Hasan, Gulam Mustafa Hassan, Md. Imtaiyaz Sohal, Sukhwinder Singh Shamsi, Anas Alam, Manzar ACS Omega [Image: see text] Non-small cell lung carcinoma (NSCLC) is the most common cancer globally. Phytochemicals and small molecule inhibitors significantly prevent varying types of cancers, including NSCLC. These therapeutic molecules serve as important sources for new drugs that interfere with cellular proliferation, apoptosis, metastasis, and angiogenesis by regulating signaling pathways. These molecules affect several cellular signaling cascades, including p53, NF-κB, STAT3, RAS, MAPK/ERK, Wnt, and AKT/PI3K, and are thus implicated in the therapeutic management of cancers. This review aims to describe the bioactive compounds and small-molecule inhibitors, their anticancer action, and targeting cellular signaling cascades in NSCLC. We highlighted the therapeutic potential of Epigallocatechin gallate (EGCG), Perifosine, ABT-737, Thymoquinine, Quercetin, Venetoclax, Gefitinib, and Genistein. These compounds are implicated in the therapeutic management of NSCLC. This review further offers deeper mechanistic insights into different signaling pathways that could be targeted for NSCLC therapy by phytochemicals and small-molecule inhibitors. American Chemical Society 2023-07-17 /pmc/articles/PMC10398694/ /pubmed/37546685 http://dx.doi.org/10.1021/acsomega.3c02424 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Hasan, Gulam Mustafa Hassan, Md. Imtaiyaz Sohal, Sukhwinder Singh Shamsi, Anas Alam, Manzar Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma |
title | Therapeutic Targeting
of Regulated Signaling Pathways
of Non-Small Cell Lung Carcinoma |
title_full | Therapeutic Targeting
of Regulated Signaling Pathways
of Non-Small Cell Lung Carcinoma |
title_fullStr | Therapeutic Targeting
of Regulated Signaling Pathways
of Non-Small Cell Lung Carcinoma |
title_full_unstemmed | Therapeutic Targeting
of Regulated Signaling Pathways
of Non-Small Cell Lung Carcinoma |
title_short | Therapeutic Targeting
of Regulated Signaling Pathways
of Non-Small Cell Lung Carcinoma |
title_sort | therapeutic targeting
of regulated signaling pathways
of non-small cell lung carcinoma |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398694/ https://www.ncbi.nlm.nih.gov/pubmed/37546685 http://dx.doi.org/10.1021/acsomega.3c02424 |
work_keys_str_mv | AT hasangulammustafa therapeutictargetingofregulatedsignalingpathwaysofnonsmallcelllungcarcinoma AT hassanmdimtaiyaz therapeutictargetingofregulatedsignalingpathwaysofnonsmallcelllungcarcinoma AT sohalsukhwindersingh therapeutictargetingofregulatedsignalingpathwaysofnonsmallcelllungcarcinoma AT shamsianas therapeutictargetingofregulatedsignalingpathwaysofnonsmallcelllungcarcinoma AT alammanzar therapeutictargetingofregulatedsignalingpathwaysofnonsmallcelllungcarcinoma |